CELG-RI
BRISTOL MYERS SQUIBB CO
NYSE · Healthcare · Drug Manufacturers - General · US
$0.12
+9.71%Latest reported
- Last report date
- Oct 29, 2026
- EPS actual
- $1.06
- EPS estimate
- $1.72
- Revenue actual
- $13.1B
- Revenue estimate
- $12.6B
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 2
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -14.1%
- Revenue beats (12Q)
- 6
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Oct 29, 2026 | $1.72 | $1.06 | Miss -38.37% | $13.1B |
| Jul 30, 2026 | $1.60 | $2.04 | Beat 27.50% | $13.0B |
| Apr 30, 2026 | $1.42 | $1.58 | Beat 11.27% | $11.5B |
| Feb 5, 2026 | $1.23 | $0.53 | Miss -56.67% | $12.5B |
| Oct 30, 2025 | $1.52 | $1.08 | Miss -28.95% | $12.2B |
| Apr 24, 2025 | $1.49 | $1.21 | Miss -18.79% | $11.2B |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Feb 4, 2027